A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
This study is a first-in-human (FIH), Phase I, single center, randomized, double-blind, placebo-controlled, sequential group study in healthy male subjects to assess the safety, tolerability and PK of single ascending oral doses of GLPG2737 and multiple ascending oral doses of GLPG2737 administered for 14 days.
Epistemonikos ID: b7000847605e487945bae9513976d67635a3efaf
First added on: May 21, 2024